The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety of trastuzumab in HER2-positive primary breast cancer in Japan: Initial safety report for the large-scale cohort study (JBCRG C-01).
Naohito Yamamoto
No relevant relationships to disclose
Hiroyasu Yamashiro
No relevant relationships to disclose
Hiroji Iwata
Honoraria - Chugai Pharma
Norikazu Masuda
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
Shoichiro Ohtani
No relevant relationships to disclose
Masato Takahashi
No relevant relationships to disclose
Kosuke Yamazaki
No relevant relationships to disclose
Makoto Kato
No relevant relationships to disclose
Shinji Ohno
No relevant relationships to disclose
Katsumasa Kuroi
No relevant relationships to disclose
Kazuhiko Yamagami
No relevant relationships to disclose
Takashi Morimoto
No relevant relationships to disclose
Yoshie Hasegawa
No relevant relationships to disclose
Toshimi Takano
No relevant relationships to disclose
Takayuki Kadoya
No relevant relationships to disclose
Mitsuchika Hosoda
No relevant relationships to disclose
Hajime Abe
No relevant relationships to disclose
Satoshi Morita
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
Shinji Yasuno
No relevant relationships to disclose
Masakazu Toi
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma